Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering.
South San Francisco-based Principia Biopharma is looking to become a publicly traded company and is aiming for a $86 million initial public offering.
Weeks after securing $52 million in a Series C financing, Magenta Therapeutics is eying the raising of $100 million in an initial public offering two years after it was launched by Third Rock Ventures and Atlas Venture with $48.5 million in Series A financing.
Moderna Therapeutics announced that the company closed on its seventh private equity financing round worth $500 million.
NeuroPace Inc. raised $74 million in equity funding as the medical device maker looks to rapidly expand commercialization of its device to treat epileptic seizures.
The Biotechnology Industry Organization released a report titled: Emerging Therapeutic Company Investment and Deal Trends. BIO Industry Analysis says more than 90 percent of the biopharma industry is composed of small, emerging companies. According to BIO President Jim Greenwood and E. Cartier Esham, Ph.D., executive VP of BIO’s Emerging Companies Section, it is important for the trade association to better understand early-stage investor and deal-making trends in order to determine where scientific or policy issues may be affecting the ability to maintain a robust pipeline of innovative medicines.
The biotechnology arena’s financing total for 2015 reached unprecedented heights for the second straight year, according to EY’s 29th annual Beyond borders report. Biotech companies raised nearly $71 billion in 2015, well ahead of the previous record of $56 billion totaled during 2014.
A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike, attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology. German and U.S. firms are leading the way in synthetic messenger RNA, or mRNA technology, a new approach to tackling a […]
Drug distributor AmerisourceBergen Corp agreed to buy PharMEDium Healthcare Holdings Inc for $2.58 billion from private equity firm Clayton, Dubilier & Rice, expanding its business of supplying compounded drugs to hospitals. Compounding is a process in which pharma products are diluted to create doses that are not sold commercially. Increased regulatory oversight following a fungal […]
Massachusetts is once again demonstrating how important biotech and pharma companies are to the state. Of Boston Business Journal’s list of fastest-growing public companies in the state, the top nine are all life science companies—compared to seven from 2014. MassBio reported more than 900 biopharma, medical device and diagnostics companies located in Massachusetts. The top […]